Charles River Laboratories Intl. Inc vs Global X Defense Tech ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Global X Defense Tech ETF trades at $60.31. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| CRL | SHLD | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $233.60 | $78.02 |
52-Week Low | $145.57 | $58.20 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SHLD (Global X Defense Tech ETF) trades at $60.47, down 1.18% today amid bearish technical signals. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights defense sector opportunities from global military spending increases and geopolitical tensions, with SHLD positioned as a diversified play on defense technology innovation across international markets.
Outlook remains mixed with technical weakness offset by positive sector catalysts. Investment opportunity lies in exposure to rising global defense budgets and technological modernization, but risks include political uncertainty and competition from specialized ETFs. The bearish technical setup suggests cautious entry points near support levels may be prudent for long-term investors.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →